Study of MM-398 as front-line therapy in patients with HER2-negative gastric cancer

Trial Profile

Study of MM-398 as front-line therapy in patients with HER2-negative gastric cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2015 Planned initiation date changed from 1 Jun 2015 to 1 Mar 2016.
    • 09 Nov 2015 According to a Merrimack Pharmaceuticals media release, this trial will commence in 2016.
    • 11 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top